导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -23.02% | 4478/4773 |
| 近一周 | -3.89% | 4926/5465 |
| 近一月 | -7.12% | 4454/5421 |
| 近一季 | -2.32% | 1352/5231 |
| 近半年 | -20.47% | 4401/4920 |
| 近一年 | -33.09% | 4282/4394 |
| 近两年 | -16.00% | 2948/2954 |
| 近三年 | -48.12% | 2247/2253 |
| 成立以来 | 130.70% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.00% 4254/4961 |
-19.55% 4856/5312 |
- - |
- - |
| 2025 | -12.46% 3395/4813 |
0.05% 1991/3635 |
-9.68% 3619/4076 |
6.30% 3535/4524 |
-8.88% 3966/4813 |
| 2024 | -10.96% 2348/3463 |
-0.23% 1088/2808 |
-14.22% 2658/3014 |
16.08% 1543/3129 |
-10.37% 2984/3463 |
| 2023 | -18.48% 1808/2656 |
7.62% 550/2280 |
-16.64% 2258/2385 |
1.70% 287/2515 |
-10.65% 2388/2655 |
| 2022 | -10.87% 220/2207 |
-22.24% 1690/1919 |
25.11% 11/2016 |
-11.17% 499/2113 |
3.14% 760/2208 |
| 2021 | -0.71% 759/1822 |
-10.52% 1117/1255 |
19.10% 165/1330 |
-12.86% 1319/1466 |
6.92% 198/1822 |
| 2020 | 117.96% 9/1250 |
-8.48% 612/1028 |
36.88% 14/1067 |
20.41% 54/1164 |
44.50% 12/1184 |
| 2019 | 83.87% 20/1092 |
50.85% 6/754 |
10.40% 5/804 |
5.34% 155/850 |
4.81% 778/918 |
| 2018 | -23.72% 297/834 |
- - |
- - |
- - |
-21.44% 672/691 |
| 2017 | 48.72% 12/714 |
- - |
- - |
- - |
- - |
| 2016 | 5.73% 17/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华酒A VS. 长安沪深300非周期A(740101) |